STOCK TITAN

[144] ANI Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 7,292 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $692,270.40 and stated approximate sale date of 09/03/2025. The filer identifies prior restricted stock acquisitions of 3,000 shares on 04/27/2023 and 4,292 shares on 03/23/2022, both received from the issuer, and discloses a sale during the past three months of 5,421 shares for $486,406.81 on 08/20/2025. The form includes the standard representation that the seller is not aware of any undisclosed material adverse information.

Avviso Form 144 per ANI Pharmaceuticals, Inc. (ANIP) segnala una proposta di vendita di 7.292 azioni di azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ con un valore di mercato complessivo di $692.270,40 e una data approssimativa di vendita indicata al 03/09/2025. Il dichiarante indica acquisizioni precedenti di azioni soggette a restrizioni: 3.000 azioni il 27/04/2023 e 4.292 azioni il 23/03/2022, entrambe ricevute dall'emittente, e dichiara una vendita negli ultimi tre mesi di 5.421 azioni per $486.406,81 in data 20/08/2025. Il modulo riporta la consueta dichiarazione che il venditore non è a conoscenza di informazioni materiali sfavorevoli non divulgate.

Aviso Formulario 144 para ANI Pharmaceuticals, Inc. (ANIP) informa sobre una propuesta de venta de 7.292 acciones de acciones ordinarias a través de Morgan Stanley Smith Barney LLC en NASDAQ, con un valor de mercado agregado de $692.270,40 y una fecha aproximada de venta indicada para el 03/09/2025. El declarante identifica adquisiciones previas de acciones restringidas de 3.000 acciones el 27/04/2023 y 4.292 acciones el 23/03/2022, ambas recibidas del emisor, y revela una venta en los últimos tres meses de 5.421 acciones por $486.406,81 el 20/08/2025. El formulario incluye la declaración habitual de que el vendedor no tiene conocimiento de información material desfavorable no divulgada.

ANI Pharmaceuticals, Inc. (ANIP) 관련 Form 144 통지는 NASDAQ에서 Morgan Stanley Smith Barney LLC를 통해 보통주 7,292주를 매도할 예정이며, 총 시가 $692,270.40이고 예정 매각일은 2025-09-03로 기재되어 있다고 보고합니다. 제출자는 발행인으로부터 취득한 제한주식으로 2023-04-27에 3,000주2022-03-23에 4,292주를 이전에 취득했음을 밝히고, 최근 3개월 내 2025-08-20에 5,421주를 $486,406.81에 매각한 사실을 공개합니다. 서식에는 매도인이 공개되지 않은 중대한 불리한 정보가 없음을 알고 있지 않다는 표준 진술이 포함되어 있습니다.

Avis Formulaire 144 pour ANI Pharmaceuticals, Inc. (ANIP) signale une proposition de vente de 7 292 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur de marché totale de 692 270,40 $ et une date approximative de vente indiquée au 03/09/2025. Le déclarant indique des acquisitions antérieures d'actions restreintes de 3 000 actions le 27/04/2023 et 4 292 actions le 23/03/2022, toutes deux reçues de l'émetteur, et divulgue une vente au cours des trois derniers mois de 5 421 actions pour 486 406,81 $ le 20/08/2025. Le formulaire contient la déclaration standard selon laquelle le vendeur n'a connaissance d'aucune information défavorable significative non divulguée.

Formular 144-Mitteilung für ANI Pharmaceuticals, Inc. (ANIP) meldet einen geplanten Verkauf von 7.292 Aktien von Stammaktien über Morgan Stanley Smith Barney LLC an der NASDAQ mit einem zusammengefassten Marktwert von $692.270,40 und einem angegebenen ungefähren Verkaufstermin am 03.09.2025. Der Einreicher gibt frühere Erwerbe von eingeschränkten Aktien an: 3.000 Aktien am 27.04.2023 und 4.292 Aktien am 23.03.2022, beide vom Emittenten erhalten, und legt einen Verkauf innerhalb der letzten drei Monate von 5.421 Aktien für $486.406,81 am 20.08.2025 offen. Das Formular enthält die übliche Erklärung, dass dem Verkäufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insider sale disclosed; transaction size is small relative to total shares outstanding and appears routine.

The filing notifies the market of a planned sale of 7,292 common shares through Morgan Stanley Smith Barney with an indicated value of $692,270.40 and references recent restricted stock grants and a recent sale of 5,421 shares generating $486,406.81. With 21,688,772 shares outstanding, the planned sale represents roughly 0.03% of outstanding shares, suggesting limited immediate dilution or market impact. The disclosure is consistent with Rule 144 mechanics for restricted securities and includes the standard attestation about undisclosed material information.

TL;DR: Document fulfills disclosure obligations under Rule 144; provides dates and amounts for grants and recent sales.

The filer documents acquisition dates for restricted stock awards and lists a broker and planned sale date, meeting procedural requirements for public notice of proposed insider sales. The filing contains the prescribed representation regarding material nonpublic information and highlights a recent sale within the last three months. There are no statements here about changes in management, related-party issues, or other governance events; thus the filing appears to be a routine transparency disclosure rather than a governance red flag.

Avviso Form 144 per ANI Pharmaceuticals, Inc. (ANIP) segnala una proposta di vendita di 7.292 azioni di azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ con un valore di mercato complessivo di $692.270,40 e una data approssimativa di vendita indicata al 03/09/2025. Il dichiarante indica acquisizioni precedenti di azioni soggette a restrizioni: 3.000 azioni il 27/04/2023 e 4.292 azioni il 23/03/2022, entrambe ricevute dall'emittente, e dichiara una vendita negli ultimi tre mesi di 5.421 azioni per $486.406,81 in data 20/08/2025. Il modulo riporta la consueta dichiarazione che il venditore non è a conoscenza di informazioni materiali sfavorevoli non divulgate.

Aviso Formulario 144 para ANI Pharmaceuticals, Inc. (ANIP) informa sobre una propuesta de venta de 7.292 acciones de acciones ordinarias a través de Morgan Stanley Smith Barney LLC en NASDAQ, con un valor de mercado agregado de $692.270,40 y una fecha aproximada de venta indicada para el 03/09/2025. El declarante identifica adquisiciones previas de acciones restringidas de 3.000 acciones el 27/04/2023 y 4.292 acciones el 23/03/2022, ambas recibidas del emisor, y revela una venta en los últimos tres meses de 5.421 acciones por $486.406,81 el 20/08/2025. El formulario incluye la declaración habitual de que el vendedor no tiene conocimiento de información material desfavorable no divulgada.

ANI Pharmaceuticals, Inc. (ANIP) 관련 Form 144 통지는 NASDAQ에서 Morgan Stanley Smith Barney LLC를 통해 보통주 7,292주를 매도할 예정이며, 총 시가 $692,270.40이고 예정 매각일은 2025-09-03로 기재되어 있다고 보고합니다. 제출자는 발행인으로부터 취득한 제한주식으로 2023-04-27에 3,000주2022-03-23에 4,292주를 이전에 취득했음을 밝히고, 최근 3개월 내 2025-08-20에 5,421주를 $486,406.81에 매각한 사실을 공개합니다. 서식에는 매도인이 공개되지 않은 중대한 불리한 정보가 없음을 알고 있지 않다는 표준 진술이 포함되어 있습니다.

Avis Formulaire 144 pour ANI Pharmaceuticals, Inc. (ANIP) signale une proposition de vente de 7 292 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur de marché totale de 692 270,40 $ et une date approximative de vente indiquée au 03/09/2025. Le déclarant indique des acquisitions antérieures d'actions restreintes de 3 000 actions le 27/04/2023 et 4 292 actions le 23/03/2022, toutes deux reçues de l'émetteur, et divulgue une vente au cours des trois derniers mois de 5 421 actions pour 486 406,81 $ le 20/08/2025. Le formulaire contient la déclaration standard selon laquelle le vendeur n'a connaissance d'aucune information défavorable significative non divulguée.

Formular 144-Mitteilung für ANI Pharmaceuticals, Inc. (ANIP) meldet einen geplanten Verkauf von 7.292 Aktien von Stammaktien über Morgan Stanley Smith Barney LLC an der NASDAQ mit einem zusammengefassten Marktwert von $692.270,40 und einem angegebenen ungefähren Verkaufstermin am 03.09.2025. Der Einreicher gibt frühere Erwerbe von eingeschränkten Aktien an: 3.000 Aktien am 27.04.2023 und 4.292 Aktien am 23.03.2022, beide vom Emittenten erhalten, und legt einen Verkauf innerhalb der letzten drei Monate von 5.421 Aktien für $486.406,81 am 20.08.2025 offen. Das Formular enthält die übliche Erklärung, dass dem Verkäufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What insider sale does ANIP's Form 144 disclose?

The form discloses a proposed sale of 7,292 shares of ANIP common stock through Morgan Stanley Smith Barney with an aggregate market value of $692,270.40 and an approximate sale date of 09/03/2025.

What recent sales by the filer are reported in the past three months for ANIP?

The filing reports a sale on 08/20/2025 of 5,421 shares of common stock for gross proceeds of $486,406.81.

How many ANIP shares outstanding are shown on the Form 144?

The form indicates 21,688,772 shares of common stock outstanding.

When were the restricted stock grants acquired by the filer?

The filer received 4,292 shares as restricted stock on 03/23/2022 and 3,000 shares on 04/27/2023, both from the issuer.

Which broker is handling the proposed ANIP share sale?

The broker named on the form is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
Ani Pharmaceutic

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data

2.08B
18.35M
10.46%
98.34%
10.17%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BAUDETTE